ES2733929T3 - Una combinación farmacéutica para el tratamiento del melanoma - Google Patents

Una combinación farmacéutica para el tratamiento del melanoma Download PDF

Info

Publication number
ES2733929T3
ES2733929T3 ES14822283T ES14822283T ES2733929T3 ES 2733929 T3 ES2733929 T3 ES 2733929T3 ES 14822283 T ES14822283 T ES 14822283T ES 14822283 T ES14822283 T ES 14822283T ES 2733929 T3 ES2733929 T3 ES 2733929T3
Authority
ES
Spain
Prior art keywords
inhibitor
melanoma
compound
braf
antineoplastic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14822283T
Other languages
English (en)
Spanish (es)
Inventor
Veena Agarwal
Giridharan Periyasamy
Maggie Rathos
Ankita Srivastava
Sreesha Srinivasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Application granted granted Critical
Publication of ES2733929T3 publication Critical patent/ES2733929T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES14822283T 2013-07-12 2014-07-11 Una combinación farmacéutica para el tratamiento del melanoma Active ES2733929T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845749P 2013-07-12 2013-07-12
PCT/IB2014/063022 WO2015004636A1 (en) 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma

Publications (1)

Publication Number Publication Date
ES2733929T3 true ES2733929T3 (es) 2019-12-03

Family

ID=52279411

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14822283T Active ES2733929T3 (es) 2013-07-12 2014-07-11 Una combinación farmacéutica para el tratamiento del melanoma

Country Status (12)

Country Link
US (4) US11007174B2 (enExample)
EP (1) EP3019166B1 (enExample)
JP (5) JP6568060B2 (enExample)
CN (3) CN105530931B (enExample)
AR (1) AR096892A1 (enExample)
AU (1) AU2014288857B2 (enExample)
CA (1) CA2917742C (enExample)
DK (1) DK3019166T3 (enExample)
ES (1) ES2733929T3 (enExample)
IL (1) IL243572B (enExample)
TW (4) TWI839690B (enExample)
WO (1) WO2015004636A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019166T3 (da) 2013-07-12 2019-07-29 Piramal Entpr Ltd A Pharmaceutical Combination for the Treatment of Melanoma
WO2016197129A1 (en) 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
JP7405408B2 (ja) * 2017-05-16 2023-12-26 バイオメッド バレー ディスカバリーズ，インコーポレイティド 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
IL274663B2 (en) 2017-11-17 2024-01-01 Univ Illinois Cancer therapy by degrading dual mek signaling
CN107827726B (zh) * 2017-11-28 2020-09-15 辽宁中医药大学 马齿苋中化合物Oleracone E及其提取分离方法
CN108591464B (zh) * 2018-06-28 2020-06-23 宁波奥克斯高科技有限公司 一种气体绝缘开关柜用密封结构
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
MX2021012248A (es) * 2019-04-11 2022-03-11 Mei Pharma Inc Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN112168821B (zh) * 2020-11-09 2022-10-14 中南大学湘雅医院 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用
WO2022109307A1 (en) * 2020-11-19 2022-05-27 Mei Pharma, Inc. Treatment of kras mutant cancers
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
AU2001242629B2 (en) 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
US6683095B2 (en) 2000-05-03 2004-01-27 Lg Life Sciences Ltd. CDK inhibitors having 3-hydroxychromen-4-one structure
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
AU2003276453A1 (en) 2002-11-06 2004-06-07 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
CN1889943A (zh) 2003-12-08 2007-01-03 美国亚利桑那大学董事会 协同抗癌组合物
AU2006223257A1 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
ES2491140T3 (es) * 2006-06-21 2014-09-05 Piramal Enterprises Limited Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
MX2009000109A (es) 2006-07-07 2009-03-16 Piramal Life Sciences Ltd Sintesis enantioselectiva de pirrolidinas sustituidas con flavonas y de sus intermediarios.
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
ATE538652T1 (de) 2007-05-15 2012-01-15 Piramal Life Sciences Ltd Synergistische pharmazeutische kombination für die behandlung von krebs
US20100152129A1 (en) * 2008-03-31 2010-06-17 Periyasamy Giridharan Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
KR20130027476A (ko) 2010-02-26 2013-03-15 피라말 엔터프라이지즈 리미티드 염증 질환을 치료하기 위한 피롤리딘으로 치환된 플라본
CN101841463B (zh) * 2010-03-05 2012-05-16 清华大学 基于sctp的多路径并发传输方法
EP2608790A4 (en) * 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
WO2012068468A1 (en) 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
AU2011330733A1 (en) 2010-11-19 2013-06-06 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a CDK inhibitor
WO2012123889A1 (en) * 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
KR20140056227A (ko) 2011-06-24 2014-05-09 피라말 엔터프라이지즈 리미티드 인간 유두종바이러스와 관련된 암의 치료를 위한 화합물
IN2014MN01546A (enExample) 2012-01-13 2015-05-08 Piramal Entpr Ltd
WO2014049515A1 (en) 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
WO2014128523A1 (en) 2013-02-19 2014-08-28 Piramal Enterprises Limited A process for preparation of an intermediate of the pyrrolidine substituted flavones
DK3019166T3 (da) 2013-07-12 2019-07-29 Piramal Entpr Ltd A Pharmaceutical Combination for the Treatment of Melanoma
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
CN111053768A (zh) 2020-04-24
CN105530931A (zh) 2016-04-27
EP3019166A4 (en) 2017-04-19
IL243572A0 (en) 2016-02-29
TW202233177A (zh) 2022-09-01
JP2019206565A (ja) 2019-12-05
CA2917742A1 (en) 2015-01-15
AU2014288857A1 (en) 2016-02-04
TW201534297A (zh) 2015-09-16
WO2015004636A1 (en) 2015-01-15
CA2917742C (en) 2020-04-14
US11007174B2 (en) 2021-05-18
JP7799508B2 (ja) 2026-01-15
US20160136132A1 (en) 2016-05-19
JP2021001186A (ja) 2021-01-07
CN117731786A (zh) 2024-03-22
US11839591B2 (en) 2023-12-12
US12383530B2 (en) 2025-08-12
JP2022068335A (ja) 2022-05-09
JP2016525097A (ja) 2016-08-22
AU2014288857B2 (en) 2019-03-14
CN105530931B (zh) 2019-11-08
US20240165076A1 (en) 2024-05-23
CN111053768B (zh) 2023-12-12
US20190282544A1 (en) 2019-09-19
TW202031253A (zh) 2020-09-01
EP3019166A1 (en) 2016-05-18
EP3019166B1 (en) 2019-05-08
DK3019166T3 (da) 2019-07-29
JP6568060B2 (ja) 2019-08-28
TWI839690B (zh) 2024-04-21
JP2024037891A (ja) 2024-03-19
AR096892A1 (es) 2016-02-03
TWI680760B (zh) 2020-01-01
IL243572B (en) 2019-10-31
US20210393589A1 (en) 2021-12-23
TW202502325A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
US12383530B2 (en) Pharmaceutical combination for the treatment of melanoma
US20250332145A1 (en) Pharmaceutical combination for the treatment of cancer
ES2312568T3 (es) Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo.
Senkal et al. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo
ES2791539T3 (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresión de DUX4
WO2023092943A1 (zh) 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用
CA2891300A1 (en) Inhibition of drug resistant cancer cells
Di Desidero et al. Metronomic chemotherapy for triple negative breast cancer?
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
US20200061054A1 (en) Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
HK1224936A1 (en) A pharmaceutical combination for the treatment of melanoma
HK1224936B (en) A pharmaceutical combination for the treatment of melanoma
CA3198190A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
Di Desidero et al. www. impactaging. com AGING, April 2016, Vol 8 No 4